Table 6.
Outcomes for BP-CCBs versus angiotensin receptor blockers (ARBs), showing percentage with each diagnosis during the exposure period, and the risk ratio. A: patients with no prior neuropsychiatric diagnosis. B: patients with a prior neuropsychiatric diagnosis.
| A: no prior neuropsychiatric diagnosis | B: with prior neuropsychiatric diagnosis | |||||
|---|---|---|---|---|---|---|
| BP-CCB (%) | ARB (%) | Risk ratio (95% CI) | BP-CCB (%) | ARB (%) | Risk ratio (95% CI) | |
| Psychotic disorder | 0.6 | 0.3 | 1.80 (1.44–2.25) | 3.3 | 2.5 | 1.29 (1.16–1.45) |
| Schizophrenia | 0.2 | 0.1 | 2.39 (1.54–3.72) | 1.3 | 1.2 | 1.14 (0.96–1.36) |
| Affective disorder | 6.6 | 6.6 | 1.00 (0.95–1.06) | 32.7 | 31.6 | 1.04 (1.01–1.07) |
| Bipolar disorder | 0.4 | 0.3 | 1.25 (0.99–1.57) | 4.1 | 3.5 | 1.18 (1.07–1.30) |
| Major depressive disorder | 5.9 | 6.0 | 0.99 (0.94–1.05) | 29.0 | 28.1 | 1.03 (1.00–1.06) |
| Anxiety disorder | 7.3 | 8.0 | 0.91 (0.87–0.95) | 31.1 | 31.0 | 1.00 (0.97–1.03) |
| Sleep disorder | 8.0 | 11.3 | 0.72 (0.69–0.75) | 28.7 | 33.4 | 0.86 (0.83–0.88) |
| Substance use disorder | 5.8 | 4.4 | 1.31 (1.23–1.39) | 28.2 | 24.0 | 1.17 (1.14–1.21) |
| Delirium | 1.0 | 1.0 | 1.07 (0.93–1.23) | 4.3 | 2.7 | 1.58 (1.42–1.75) |
| Dementia | 1.0 | 0.8 | 1.27 (1.10–1.48) | 3.6 | 2.9 | 1.25 (1.12–1.39) |
| Movement disorder | 1.2 | 1.5 | 0.82 (0.73–0.93) | 6.1 | 5.5 | 1.11 (1.03–1.20) |
| Any of the above | 21.8 | 23.2 | 0.94 (0.92–0.97) | 72.3 | 72.6 | 0.99 (0.98–1.01) |
| Negative control outcomesa | 0.88 (0.80–0.96) | 0.91 (0.85–0.98) | ||||
Risk ratios in bold have 95% confidence intervals not including 1.
aMean of 12 negative control outcomes. Full details in Supplementary Table 6C.
b35% on verapamil, 67% on diltiazem. Numbers exceed 100% as some patients were prescribed both drugs.
c38% on verapamil, 66% on diltiazem. Numbers exceed 100% as some patients prescribed both drugs.